Alimera Sciences Management
Management criteria checks 0/4
Alimera Sciences' CEO is Rick Eiswirth, appointed in Jan 2019, has a tenure of 5.33 years. total yearly compensation is $3.26M, comprised of 18.5% salary and 81.5% bonuses, including company stock and options. directly owns 0.62% of the company’s shares, worth $1.04M. The average tenure of the management team and the board of directors is 1.8 years and 1.9 years respectively.
Key information
Rick Eiswirth
Chief executive officer
US$3.3m
Total compensation
| CEO salary percentage | 18.5% |
| CEO tenure | 5.3yrs |
| CEO ownership | 0.6% |
| Management average tenure | 1.8yrs |
| Board average tenure | 1.9yrs |
Recent management updates
Recent updates
Alimera Sciences, Inc.'s (NASDAQ:ALIM) Shares Not Telling The Full Story
Feb 15
Is Alimera Sciences (NASDAQ:ALIM) A Risky Investment?
Dec 30Investors Holding Back On Alimera Sciences, Inc. (NASDAQ:ALIM)
Oct 13Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?
Sep 13Alimera confirmatory trial testing Iluvien in diabetic macular edema patients shows positive data
Oct 06Alimera's eye inflammation Iluvien injection granted reimbursement in Ireland
Sep 20Alimera granted reimbursement in Portugal for eye inflammation Iluvien injection
Aug 09Alimera granted pricing, reimbursement in France for eye inflammation Iluvien injection
Jul 22Alimera gets Italian nod for its Iluvien injection to treat a form of eye inflammation
Jul 08Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?
Mar 24Is Alimera Sciences, Inc. (NASDAQ:ALIM) Worth US$5.7 Based On Its Intrinsic Value?
Nov 06Why Alimera Sciences' (NASDAQ:ALIM) Earnings Are Weaker Than They Seem
Aug 24Alimera Sciences' (NASDAQ:ALIM) Shareholders Are Down 75% On Their Shares
Feb 11Alimera Sciences (ALIM) Investor Presentation - Slideshow
Nov 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$23m |
| Dec 31 2023 | US$3m | US$603k | -US$21m |
| Sep 30 2023 | n/a | n/a | -US$21m |
| Jun 30 2023 | n/a | n/a | -US$25m |
| Mar 31 2023 | n/a | n/a | -US$17m |
| Dec 31 2022 | US$974k | US$580k | -US$18m |
| Sep 30 2022 | n/a | n/a | -US$18m |
| Jun 30 2022 | n/a | n/a | -US$17m |
| Mar 31 2022 | n/a | n/a | -US$7m |
| Dec 31 2021 | US$890k | US$550k | -US$4m |
| Sep 30 2021 | n/a | n/a | -US$1m |
| Jun 30 2021 | n/a | n/a | US$2m |
| Mar 31 2021 | n/a | n/a | -US$8m |
| Dec 31 2020 | US$888k | US$550k | -US$5m |
| Sep 30 2020 | n/a | n/a | -US$4m |
| Jun 30 2020 | n/a | n/a | -US$6m |
| Mar 31 2020 | n/a | n/a | -US$9m |
| Dec 31 2019 | US$977k | US$525k | -US$10m |
| Sep 30 2019 | n/a | n/a | -US$12m |
| Jun 30 2019 | n/a | n/a | US$19m |
| Mar 31 2019 | n/a | n/a | US$22m |
| Dec 31 2018 | US$831k | US$495k | US$17m |
| Sep 30 2018 | n/a | n/a | US$11m |
| Jun 30 2018 | n/a | n/a | -US$22m |
| Mar 31 2018 | n/a | n/a | -US$23m |
| Dec 31 2017 | US$811k | US$425k | -US$22m |
Compensation vs Market: Rick's total compensation ($USD3.26M) is above average for companies of similar size in the US market ($USD1.55M).
Compensation vs Earnings: Rick's compensation has increased whilst the company is unprofitable.
CEO
Rick Eiswirth (55 yo)
5.3yrs
Tenure
US$3,261,480
Compensation
Mr. Richard S. Eiswirth, Jr., also known as Rick, served as Interim Chief Financial Officer at Alimera Sciences, Inc. since 2022. He has been President of Alimera Sciences, Inc. since January 1, 2016 until...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 5.3yrs | US$3.26m | 0.62% $ 1.0m | |
| Chief Operating Officer | less than a year | US$1.39m | 0.0018% $ 2.9k | |
| President of International Operations | less than a year | US$1.02m | 0.23% $ 378.5k | |
| Co-Founder | 20.9yrs | US$541.72k | 0.36% $ 599.2k | |
| CFO & Treasurer | less than a year | no data | no data | |
| VP, General Counsel & Secretary | 5.5yrs | no data | no data | |
| Chief Retina Specialist | 3yrs | no data | no data | |
| President of U.S. Operations | less than a year | no data | no data |
1.8yrs
Average Tenure
54.5yo
Average Age
Experienced Management: ALIM's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 5.3yrs | US$3.26m | 0.62% $ 1.0m | |
| Independent Director | 14.1yrs | US$186.31k | 0.00096% $ 1.6k | |
| Director | less than a year | US$96.42k | 0% $ 0 | |
| Director | 1.3yrs | US$124.63k | 0% $ 0 | |
| Independent Director | 4.8yrs | US$172.21k | 0.019% $ 32.0k | |
| Independent Director | 1.2yrs | US$151.70k | 0% $ 0 | |
| Chairman of the Board | 1.2yrs | US$165.75k | 0% $ 0 | |
| Director | 2.5yrs | US$172.52k | 0% $ 0 |
1.9yrs
Average Tenure
52.5yo
Average Age
Experienced Board: ALIM's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.